Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REVLIMID vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Multiple myeloma (in combination with dexamethasone),Myelodysplastic syndromes (MDS) associated with deletion 5q abnormality,Mantle cell lymphoma,Follicular lymphoma (in combination with rituximab)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Lenalidomide is primarily metabolized via hydrolysis, with minor involvement of CYP1A2 and CYP3A4. The major route of elimination is renal excretion of unchanged drug; approximately 67% of the dose is excreted unchanged in urine.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Approximately 30% bound to plasma proteins, primarily albumin.
Approximately 90–95% bound, primarily to albumin.
Volume of distribution (Vd) is approximately 0.6-1.0 L/kg, indicating distribution into total body water and some tissue binding.
0.46–0.64 L/kg; indicates distribution into total body water.
Absolute oral bioavailability is approximately 33% (range 20-50%) due to first-pass metabolism. Food does not significantly alter bioavailability.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
For Cr Cl ≥60 m L/min: start at 10 mg daily; Cr Cl 30-60 m L/min: start at 5 mg daily; Cr Cl <30 m L/min: 5 mg every other day; for dialysis patients: 5 mg three times weekly after dialysis.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
No specific Child-Pugh based dose adjustments provided in labeling; use caution and monitor for toxicity in hepatic impairment.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Safety and efficacy not established; not recommended for pediatric use outside clinical trials.
Not established; safety and efficacy not studied in pediatric patients.
No specific dose adjustment based solely on age; monitor renal function and adjust per renal guidelines as elderly often have decreased Cr Cl.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Revlimid (lenalidomide) can cause fetal harm. Women of childbearing potential must use effective contraception and undergo pregnancy testing prior to and during therapy. There is an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. The drug is contraindicated in pregnant women.
None
Hematologic toxicity: Neutropenia and thrombocytopenia are common, requiring dose adjustments.,Thromboembolism: Increased risk of DVT, PE, and stroke; consider prophylactic anticoagulation or antiplatelet therapy.,Second primary malignancies: Risk of development of other cancers (e.g., AML, MDS) in patients receiving lenalidomide.,Hepatotoxicity: Elevations of liver enzymes have been reported.,Allergic reactions: Including angioedema and Stevens-Johnson syndrome.,Renal impairment: Requires dose adjustment; monitor renal function.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Pregnancy (due to teratogenicity),Women of childbearing potential not using effective contraception,Hypersensitivity to lenalidomide or any component of the formulation
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid grapefruit and grapefruit juice; they may increase lenalidomide exposure. No other significant food interactions are known.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth defects including limb reduction, cardiac anomalies, and neural tube defects. Risk is highest during the first trimester but extends throughout gestation.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
It is unknown if lenalidomide is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated. M/P ratio is not available.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
There are no dose adjustments for pregnancy because the drug is contraindicated; it must be discontinued immediately if pregnancy occurs. No pharmacokinetic studies in pregnancy are available.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Monitor for thromboembolic events; use with aspirin or anticoagulant prophylaxis. Perform pregnancy tests weekly during first month, then monthly in women of childbearing potential. Dose reduce for Cr Cl <60 m L/min. Avoid in severe hepatic impairment (Child-Pugh C).
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Do not share this medication with others; it can cause severe birth defects.,Use two forms of contraception or abstain from sex during treatment and for 4 weeks after stopping.,Report any new shortness of breath, chest pain, or leg swelling immediately.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not donate blood during treatment and for 4 weeks after stopping.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REVLIMID vs CHLORZOXAZONE, answered by our medical review team.
REVLIMID is a Immunomodulatory Agent that works by Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and b FGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REVLIMID and CHLORZOXAZONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REVLIMID is: 5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REVLIMID and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REVLIMID is classified as Category C. REVLIMID (lenalidomide) is an analog of thalidomide, a known human teratogen. It is absolutely contraindicated in pregnancy. Fetal exposure can cause severe, life-threatening birth. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.